CentoMetabolic® Panel for Integrated Multiomic Testing for Metabolic Diseases
Combining genetic and biochemical testing to provide the most comprehensive screening for rare metabolic conditions
Combining genetic and biochemical testing to provide the most comprehensive screening for rare metabolic conditions
CENTOGENE announced today that Dr. Flemming Ornskov has been appointed to the Supervisory Board and has been elected Non-Executive Chairman. His appointment is effective April 1, 2019.
As part of an exchange with senior business and academic leaders, and state of Mecklenburg-Vorpommern (M-V) government representatives, a discussion and analysis workshop was held today on ‘Digitization in Mecklenburg-Vorpommern’.
CENTOGENE today announced a 12-month strategic collaboration with Sarepta Therapeutics, Inc. for the identification of patients with Duchenne muscular dystrophy (DMD) in the Middle East and North Africa region.
CENTOGENE, a rare disease company committed to improving the lives of rare disease patients by providing solutions that accelerate the […]
CENTOGENE today announced the expansion of its clinical studies team, with the appointment of a number of clinical researchers to support its U.S. laboratory operations located in Cambridge, Massachusetts.
CENTOGENE today announced that it has been recommended for re-accreditation from the College of American Pathologists (CAP) for its flagship […]
CENTOGENE is pleased to provide a corporate update, including recent business unit developments and a look ahead to 2019. “This […]
CENTOGENE and Chiesi Germany today announced a strategic collaboration in lysosomal storage disease with special focus on Alpha Mannosidosis (AM) […]
The College of American Pathologists (CAP), a Center for Medicare and Medicaid Services (CMS)-approved accreditation authority, has awarded CENTOGENE AG accreditation to the ISO15189 standard under the CAP 15189SM Accreditation Program.
Provides physicians with virtual encyclopedia of genetic information at their fingertips for improved and efficient diagnosis of rare diseases
CENTOGENE and Denali Therapeutics (NASDAQ: DNLI) today announced a strategic collaboration for the global identification and recruitment of LRRK2-positive Parkinson’s disease (PD) patients.
Joint drug discovery projects combine CENTOGENE’s patient access and biomarker expertise with Evotec’s leading IPSC platform.
We are proud to have been honored with the award from the Federal State Government of Mecklenburg-Vorpommern in the category ‘Company Development’. We are committed to CENTOGENE’s founding roots in Rostock, unlocking the power of genetic insights.
CENTOGENE announced today a partnering with the Medical Faculties of the Universities of Greifswald and Rostock for the research project, “Development of diagnostic tools for personalized immune-based therapies for colon and pancreatic tumors.”
